Looks back at how lung cancer responds to chemotherapy before surgery
Reviews past records of adults with stage IIIA lung cancer given platinum chemotherapy before surgery.
Plain-language title generated from the registry record
Registry title: Pathological Response After Neoadjuvant Treatment on NSCLC
Key facts
- Where
- A Coruña, Alicante, Badalona, Barakaldo, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Valencia, and Vigo, SpainSee the 17 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at past records of adults with operable stage IIIA non-small cell lung cancer who had platinum-based treatment before surgery.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Operable stage IIIA non-small cell lung cancer, with lymph node (N2) involvement confirmed under the microscope. Diagnosed between 2010 and 2017.
- Earlier treatment
- Must have had platinum-based treatment before surgery, followed by surgery. Cannot have had chemoradiotherapy before surgery.
- Biomarker or test result
- A PET/CT scan at diagnosis is needed.
Main reasons for not taking part
- Had chemoradiotherapy before surgery
- Was not operated on after the first treatment
- Diagnosed after June 2017
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitario de A CorunaA Coruña, SpainContact: Teresa Hermida, MDTaking people
- Hospital General Universitario de AlicanteAlicante, SpainContact: Ignacio Aranda, MDTaking people
- ICO Badalona, Hospital Germans Trias i PujolBadalona, SpainContact: José Luis Mate, MDTaking people
- Hospital Universitario CrucesBarakaldo, SpainContact: Mónica Saiz, MDTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: Laura López Vilaró, MDTaking people
- Hospital Vall d'HebronBarcelona, SpainContact: Irene Sansano, MDTaking people
- ICO HospitaletL'Hospitalet de Llobregat, SpainContact: Nuria Baixeras, MDTaking people
- Hospital Dr. NegrínLas Palmas de Gran Canaria, SpainContact: María Luz Plaza, MDTaking people
- Hospital Universitario Insular de Gran CanariaLas Palmas de Gran Canaria, SpainContact: Maria del Carmen Camacho, MDTaking people
- Hospital 12 de OctubreMadrid, SpainContact: Ana Belén Enguita, MDTaking people
- Hospital Clínico San CarlosMadrid, SpainContact: Melchor Saiz Pardo, MDTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainContact: Federico Rojo, MDTaking people
- Hospital Universitario La PazMadrid, SpainContact: Isabel Esteban, MDTaking people
- Hospital Universitario Puerta de HierroMajadahonda, SpainContact: Mariano Provencio, MDTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainContact: Pino Flores, MDTaking people
- Hospital Universitario la FeValencia, SpainContact: Nuria Mancheño, MDTaking people
- Complejo Hospitalario Universitario de VigoVigo, SpainContact: Ana González, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundación GECP
- Trial code
- NCT05167487
- Record updated
- 6 February 2026
- Original description
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.Read full original descriptionShow less
Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient Outcomes
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.
Inclusion: Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer [AJCC] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP; Patients with histologically N2 involvement confirmed; Patients diagnosed as stage IIIA from 2010 and 2017; Patients who have received neoadjuvant platinum-based treatment and surgery; Age ≥ 18 years at time of study entry; PET /TC at diagnosis.
Exclusion: Patients who received chemoradiotherapy neoadjuvant treatment; Patients who were not resected after neoadjuvant treatment; Patients who were diagnosed after June 2017.